Combination therapy for large liver cancer tumors
Part of Cancer, Digestive system clinical trials.
This trial tests whether a combination of two treatments—chemoembolization (DEB-TACE) plus chemotherapy given through the liver artery (RALOX-HAIC)—works better than chemoembolization alone for people with large liver cancer tumors (over 7 cm). The goal is to see if the combination shrinks tumors more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have liver cancer that is confirmed by a biopsy or imaging tests.
- You have at least one liver tumor that is larger than 7 cm (about 3 inches).
- If your tumor came back after surgery or ablation, you can still join.
- Your liver function is good enough (Child-Pugh score 5-7) and you can do daily activities with little trouble (ECOG score 0 or 1).
- Your blood counts and kidney function are within safe limits (platelets at least 75,000, white blood cells at least 3,000, and other tests normal).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding a second liver-directed treatment (hepatic artery infusion) to the usual combination of targeted therapy (lenvatinib) and chemoembolization (DEB-TACE) for people with large liver cancer that has spread into the portal vein, to see if the triple therapy works better.
This trial tests a combination of two drugs (lenvatinib and sintilimab) plus a liver-directed treatment (DEB-TACE) with or without another liver treatment (HAIC) for people with large liver cancer (over 7 cm) that has spread into the main blood vessel of the liver. The goal is to see if adding HAIC helps shrink the cancer more effectively.
This trial is testing a combination of two immunotherapy drugs (sintilimab and bevacizumab) plus a procedure called TACE (chemoembolization) against a targeted therapy pill (lenvatinib) plus TACE for people with advanced liver cancer. The goal is to see which approach works better to shrink tumors and improve outcomes.
This study tests combining TACE (a procedure to block the tumor's blood supply) with immunotherapy drugs for liver cancer that has not spread outside the liver. It is for people who have not had any prior treatment for their liver cancer and are healthy enough for TACE.
This trial combines a targeted drug and immunotherapy with procedures that deliver cancer-killing beads or chemotherapy directly to your liver tumor. It is designed for people with large, inoperable liver cancer that has spread into the main vein leading to the heart.
This trial compares two treatments for people with large liver tumors. One is a liver artery chemotherapy infusion and the other is a chemo-embolization procedure. The study will see which approach works better.
Hear when a new Hepatocellular Carcinoma Non-resectable trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.